A multicenter observation study of the efficacy of cortexin and recognan (citicoline) in the treatment of cognitive impairments in chronic cerebrovascular pathology

Belova L.A.; Mashin V.V.; Dudikov E.M.; Belov D.V.; Krupennikov A.A.

doi:https://doi.org/10.17116/jnevro201911902135

Belova L.A.

Ul'ianovskiĭ gosudarstvennyĭ universitet

Mashin V.V.

Dudikov E.M.

Ulyanovsk State University, Ulyanovsk, Russia

Belov D.V.

Ulyanovsk State University, Ulyanovsk, Russia

Krupennikov A.A.

Ulyanovsk State University, Ulyanovsk, Russia

A multicenter observation study of the efficacy of cortexin and recognan (citicoline) in the treatment of cognitive impairments in chronic cerebrovascular pathology

Authors:

Belova L.A., Mashin V.V., Dudikov E.M., Belov D.V., Krupennikov A.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2): 35‑38

DOI: 10.17116/jnevro201911902135

Read: 5110 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Belova LA, Mashin VV, Dudikov EM, Belov DV, Krupennikov AA. A multicenter observation study of the efficacy of cortexin and recognan (citicoline) in the treatment of cognitive impairments in chronic cerebrovascular pathology. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2):35‑38. (In Russ.)
https://doi.org/10.17116/jnevro201911902135

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Comparative study of cognitive impairment in subgroups of bipolar affective disorder types I and II, occurring with and without psychotic symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):7-11

Relationship between stroke-associated pneumonia and long-term outcomes of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):57-61

Potential of animal-derived neuropeptides in complex therapy of diabetic neuropathy in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):83-87

The main mechanisms of development of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18

Cognitive impairment in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73

Cognitive impairment after major surgical operations. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):74-80

Analysis of cognitive status in patients with different nosologies and clinical variants of very late manifesting schizophreniform psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):88-93

The known and new ideas about the mechanism of action and the spectrum of effects of Mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33

Therapeutic potential of quercetin and its derivatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50

Study of the levocarnitine efficacy for the treatment of moderate cognitive impairment in patients with hypertension. Russian Journal of Preventive Medicine. 2025;(4):45-50

Abstract:

Objective. To make a critical assessment of the therapeutic effect of complex therapy with cortexin and recognan (citicoline) for cognitive impairments in patients with chronic cerebrovascular pathology. Material and methods. Presented is an analysis of results of the multicenter observation program to assess the efficacy of cortexin and recognan (citicoline) in the treatment of cognitive impairments in patients with chronic cerebrovascular pathology. Three hundred and nine patients with chronic cerebrovascular pathology, including 134 (43.4%) men and 175 (56.6%) women, aged from 30 to 80, average age 63.4±9.4 years, with confirmed cognitive deficit were examined. The diagnosis was established on the basis of complaints, case reports, the results of CT/MRI studies, as well as assessments of the neurological status and cognitive functions. Cognitive impairments were confirmed by the number of points on the Mini-mental state examination (MMSE) and the Clock drawing test. The assessment of depression was made with the Mini Geriatric Depression Scale (MGDS). All patients received cortexin and recognan (citicoline) («Geropharm», Russia) at doses 10 mg/day for 10 days and 1000 mg/day for 1 month, respectively. Results and conclusion. Complex therapy with cortexin and recognan (citicoline) showed high efficacy in the treatment of vascular cognitive disorders. The results of the study allow us to recommend the complex administration of cortexin and recognan (citicoline) («Geropharm», Russia) in doses of 10 mg/day for 10 days and 1000 mg/day for 1 month, respectively, for chronic cerebrovascular pathology.

Keywords:

cortexin

recognan (citicoline)

cognitive impairment

chronic cerebrovascular disorders

neuroprotection

Authors:

Belova L.A.

Ul'ianovskiĭ gosudarstvennyĭ universitet

Mashin V.V.

Dudikov E.M.

Ulyanovsk State University, Ulyanovsk, Russia

Belov D.V.

Ulyanovsk State University, Ulyanovsk, Russia

Krupennikov A.A.

Ulyanovsk State University, Ulyanovsk, Russia

Close metadata

References:

Parfenov VA. Distsirkulyatornaya entsefalopatiya i sosudistyye kognitivnyye rasstroystva. M.: IMA-PRESS; 2017. (In Russ.)
Insul’t: sovremennyye tekhnologii diagnostiki i lecheniya. Rukovodstvo dlya vrachey. Pod red. Piradova M.A., Tanashyan M.M., Maksimovoy M.Yu. 3-ye izd., dop. i pererab. M.: MEDpress-inform; 2018. (In Russ.)
Belova LA, Moiseyev MYu, Belov DV. Neĭrovizualizatsionnyye osobennosti stroyeniya tserebral’noĭ venoznoĭ sistemy u bol’nykh gipertonicheskoĭ distsirkulyatornoĭ entsefalopatiyeĭ s uchetom nalichiya konstitutsional’noĭ venoznoĭ nedostatochnosti. Sovremennaya meditsina. Rubrika Nevrologiya/Revmatologiya, Reabilitatsiya. 2018;1(9):61-67. (In Russ.)
Lucas DR, Newhouse JP. The Toxic Effect of Sodium L-Glutamate on the Inner Layers of the Retina. A.M.A. Archives of Ophthalmology. 1957;58:2:193-201. https://doi.org/10.1001/archopht.1957.00940010205006
Skvortsova VI. Snizheniye zabolevayemosti, smertnosti i invalidnosti ot insul’tov v Rossiyskoy Federatsii. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova (Spetsvypusk «Insul’t»). 2007;25-31. (In Russ.)
Gulyaeva NV. Interplay between Brain BDNF and Glutamatergic Systems: A Brief State of the Evidence and Association with the Pathogenesis of Depression. Biochemistry (Moscow). 2017;82(3):301-307. Pleiades Publishing, Ltd., 2017. Published in Russian in Biokhimiya. 2017;82(3):441-448.
Arkhipov VI, Kapralova MV, Pershina EV. Eksaytotoksichnost’ i eksperimental’nyye podkhody k neyroprotektsii. Sovremennyye Problemy Nauki i Obrazovaniya. 2013;5. (In Russ.) http://science-education.ru/ru/article/view?id=10431
Lloyd-Evans E. Acidic Ca2+ stores in neurodegeneration. Messenger (Los Angel). 2016;5(1-2):37-55. https://doi.org/10.1166/msr.2016.1054
Cisneros-Mejorado A, Gottlieb M, Ruiz A, Chara JC. Blockade and knock-out of CALHM1 channels attenuate ischemic brain damage. J Cereb Blood Flow Metab. 2017;271678X17713587. https://doi.org/10.1177/0271678X17713587
Lee BK, Jung YS. Sustained Intracellular Acidosis Triggers the Na+/H+ Exchager-1 Activation in Glutamate Excitotoxicity. Biomol Ther (Seoul). 2017;25(6):593-598. https://doi.org/10.4062/biomolther.2017.018
Ritsner MS. Brain Protection in Schizophrenia, Mood and Cognitive Disorders. Springer. 2010;663. https://doi.org/10.1007/978-90-481-8553-5
Rudenko AO, Yeltysheva TE, D’yakonov MM. Vliyaniye aminokislotnogo spektra peptidnykh organopreparatov na effektivnost’ farmakoterapii. Vestnik Rossiyskoy Voyenno-Meditsinskoy Akademii. 2017;1(57):129-136. (In Russ.)
Mashin VV, Belova LA, Chaplanova OI, Khusnullina AF, Manasyan AM. Okrytoye clinical trial of the medicine Korteksin^® at distsirkulyatorny encephalopathy. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2014;114(9):49-52. (In Russ.)
Mashin VV, Belova LA, Chaplanova OI, Khusnullina AF, Manasyan AM. An open clinical trial of cortexin in cerebral ischemia neuroscience and behavioral physiology. 2016;46:4:390-393. https://doi.org/10.1007/s11055-016-0247-4
Mashin VV, Belova LA, Bakhtogarimov IR, Bergelson TM, Sharafutdinova RR. Multicenter observational program for evaluation of the effectiveness of the drug Recognan (Citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2017;117(8):39-43. (In Russ.) https://doi.org/10.17116/jnevro20171178139-43
Mashin VV, Kadykov AS. Gipertonicheskaya entsefalopatiya. Klinika i patogenez. Nauchnoye izdaniye. Ul’yanovsk. 2002. (In Russ.)